In addition, targeting DHCR24 (24-dehydrocholesterol reductase) to increase endogenous desmosterol levels has been recognized as a promising strategy to activate the LXR transcriptional program, enhance ABCA1-mediated cholesterol efflux, and counteract atherosclerotic cardiovascular diseases [19]. This evidence concerns the gene DHCR24 and cardiovascular disorder.